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Abstract  
Bile acids (BAs) have gained mainstream attention since the discovery of their key role as 
signalling molecules in health and disease. The apical sodium dependent transporter (ASBT) 
protein located in the terminal ileum plays an important physiological role in the enterohepatic 
circulation of BAs and therefore essential for the bile acid (BA) homeostasis. Primary biliary 
cholangitis (PBC) and primary sclerosing cholangitis (PSC), the two most common cholestatic 
liver diseases are characterised by altered BA flow and bile acid composition which contribute to 
disease progression and symptom (pruritus) development. Therefore, changing the circulating 
BA pool in patients with PBC and PSC may have therapeutic implications. To this end, 
pharmacological inhibition of ASBT is fast emerging as an interesting target. In this chapter, we 
discuss recent evidence for potential therapeutic use of ASBT inhibitors (ASBTi) to treat PBC 
and PSC patients.  
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Introduction 
Primary biliary cholangitis (PBC, previously referred as primary biliary cirrhosis) is a chronic 
intrahepatic non-suppurative destructive cholangitis with a prevalence of 1 in 1000 women over 
the age of 40 years. Primary sclerosing cholangitis (PSC) is a chronic progressive cholangitis of 
intra- and extrahepatic bile ducts that predominantly affects men and has strong association with 
inflammatory bowel disease (IBD). In untreated patients these two chronic cholangiopathies lead 
to progressive loss of bile ducts, biliary fibrosis and eventually cholestatic liver cirrhosis and 
associated complications of portal hypertension and increased risk of malignancy. The aetiology 
and pathogenesis of PBC and PSC are poorly understood but cumulative evidence point to 
complex interactions between environment, genetics and immune-mediated liver injury. Clinical 
features of PBC and PSC vary greatly between patients and there are well-recognised disease-
associated symptoms, concurrent autoimmune diseases and complications. Currently available 
disease modifying and symptom-based treatment of PBC and PSC patients is unsatisfactory. For 
instance, ursodeoxycholic acid (UDCA), the current standard of care for PBC fails to improve 
liver biochemistry in ~40% of patients (UDCA non-responders) who are at higher risks of 
disease progression and poor quality of life [1]. In PSC, although UDCA improves serum liver 
tests it has no proven benefit on survival and therefore currently not recommended for routine 
treatment [2]. In addition, UDCA has limited therapeutic benefit in treating pruritus and fatigue, 
the two most common symptoms associated with PBC and PSC. Due to these limitations of 
UDCA there is an unmet need for new and effective treatment for these complex diseases. 
By definition, PBC and PSC are characterised by impaired bile flow and altered bile acid (BA) 
composition which are important pathogenic factors for initiation and development of disease 
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and symptoms. The latter is influenced by the extent of bile flow defect (cholestasis) and 
accumulation of toxic hydrophobic BAs (that cause liver cell damage) [1]. Therefore modulation 
of bile flow and BA composition is emerging as an important therapeutic strategy treating PBC 
and PSC.  
ASBT 
In health, BAs [cholic acid (CA) and chenodeoxycholic acid (CDCA)] are produced in the liver, 
secreted in the intestine and following their role in fat digestion most BAs (>95%) are re-claimed 
in the terminal ileum and returned to the liver via portal vein [3]. This efficient process of 
recycling of BAs is referred as enterohepatic circulation (EHC) which maintains the balance 
between hepatic synthesis and intestinal loss of BAs. The physiological importance of EHC has 
been well known for many decades [4] and the key proteins and sodium-dependent transporters 
involved in EHC have been characterised. It is now known that a number of specialized 
membrane transporters expressed on the apical (brush border) and basolateral membranes of the 
hepatocyte and ileal enterocytes mediate EHC of BAs (an in-depth review in [5]). Of these, the 
apical sodium dependent transporter (ASBT; also called as ileal bile acid transported, IBAT; 
gene symbol SLC10A2) located on the apical membrane of ileal enterocytes was first cloned in 
humans in 1995[6] and shown to function as a major gatekeeper for the intestinal compartment 
of EHC of BAs [7-9] (Figure 1). Indeed, by regulating the rate of biliary BA secretion it is 
considered a major determinant of BA pool size in the human body and is an essential regulator 
of lipid and cholesterol homeostasis [10]. Interestingly, ASBT mediated transport is not equal 
among BA species; conjugated (more hydrophilic) BAs are transported more efficiently than 
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unconjugated forms. Also, the affinity of ASBT is higher for dihydroxy BAs such as CDCA than 
for trihydroxy BAs such as CA, taurocholic acid (TCA) and glycocholic acid (GCA) [8].  
ASBT Inhibition 
In recent years, ASBT has gained more attention as a specific drug target to inhibit EHC and 
alter the circulating pool of BAs. There are specific effects of pharmacological inhibition of 
ASBT which have therapeutic potential. First, inhibition of intestinal reabsorption of BAs leads 
to increased BA load in the colon (Figure 1) and causes BA-induced diarrhoea. The latter effect 
is being utilised to treat constipation [11]. Second, decreased return of BAs to liver results in 
increased hepatic BA synthesis as a result of negative feedback regulation (inactivation of 
hepatic FXR)[12]. This lowers serum cholesterol level (due to increased conversion of 
cholesterol into BAs) which is an additional benefit in lipid metabolism and metabolic disorders 
and supports ASBT inhibitors as novel hypolipidaemic dugs [13]. Third, ASBT inhibition may 
have anti-diabetic action mediated through BA-TGR5 axis. BAs in the colon activate TGR5 
(highly expressed in colon) resulting in stimulation of expression and secretion of the incretin 
GLP-1, a hormone that lowers plasma glucose [14]. Finally, yet untested hypothesis suggests 
increased load of BAs in the colon may significantly impact the gut microbiome with potential 
secondary effects on cholestatic diseases [15].  
At the turn of the century, at least five classes of chemically divergent specific ASBT inhibitors 
(ASBTi) were developed (Table 1) mostly for the treatment of hypercholesterolemia. The main 
ASBTi that have entered phase 2 trials are summarised in Table 2. In the following sections we 
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review recent evidence to support therapeutic potential of ASBTi as novel therapy for PBC and 
PSC patients.  
Experimental evidence 
There are conflicting data on intestinal absorption of BAs during cholestasis. An adaptive 
regulation leading to downregulation of intestinal ASBT has been shown in both animal and 
human studies [16,17]. In contrast, increased absorption of BAs has been reported in PBC, thus 
contributing to cholestasis in this condition [18]. Nevertheless, ASBT inhibition is an attractive 
therapeutic option in cholestatic conditions based on the hypothesis that interrupting the EHC of 
BAs may also reduce the circulating BA pool and hepatic levels of potentially cytotoxic BAs.  
Early reports from non-cholestatic animal studies demonstrated that SC-435 (an ASBTi) leads to 
increased faecal BA (and diarrhoea) and reduced FXR stimulation, lower FGF19 synthesis, and 
consequently enhanced BA synthesis, expanding the BA pool and lowering plasma 
cholesterol[12,19,20]. More recently, effects of ASBTi in animal models of cholestasis have 
been reported. Miethke et al. treated mdr2-/- mice (an established animal model for chronic 
cholestasis with some features of sclerosing cholangitis) with SC-435 for 14 days. They observed 
8-fold increase in faecal BA excretion associated with 65%, 98.9% and 98.8% decrease in 
hepatic, serum and biliary concentrations of BAs, respectively. The anti-cholestatic and anti-
inflammatory effects of SC-435 was evidenced by decreased markers of liver injury; plasma 
ALT and bilirubin concentrations decreased by 86% and 93%, respectively and serum ALP by 
55%. They also observed an improvement in liver histology of sclerosing cholangitis with 
decreased fibrosis and favourable alteration in the biliary phosphatidylcholine/BAs ratio 
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indicating decreased bile toxicity. In addition, the livers from SC-435 treated mice showed 
reduction in the proinflammatory Ly6C+ and increase in anti-inflammatory Ly6C- subset of 
monocytes accompanied by reduced levels of F4/80+ CD11b+ Kupffer cells and Gr1+ CD11b+ 
neutrophils. Taken together, the results from this study demonstrated the potential of ASBTi in 
halting progression of murine sclerosing cholangitis during the early phase of disease process 
[21].  
Baghdasaryan et al. also examined the effects of a specific intestinal ASBTi (A4250, Albireo 
pharma, Sweden) in eight week old Mdr-/- (Abcb4-/-) mice (model of cholestatic liver injury and 
sclerosing cholangitis). After  four weeks of treatment with A4250 they observed reduced serum 
ALT, ALP and BA levels, decreased hepatic expression of proinflammatory (Tnf-a, Vcam1, 
Mcp-1) and pro-fibrogenic (Col1a1,Col1a2) genes and bile duct proliferation. Furthermore, 
A4250 was shown to significantly reduce bile flow and biliary BA output with preserved HCO3- 
and biliary phospholipid (PL) secretion resulting in an increased HCO3-/BA and PL/BA ratio 
[22].  
In summary, use of intestinal ASBTi in animal models of sclerosing cholangitis demonstrates 
that interruption of EHC improves cholestatic liver and bile duct injury, suggesting that ASBTi 
may represent a novel and promising treatment for cholangiopathies. 
Clinical evidence 
The three main ASBTi currently being investigated in early phase trials are: A4250, 
GSK2330672 and Lopixibat chloride (LUM001) (Table 2). In non-cholestatic population ASBTi 
have been shown to be effective in changing circulating BA levels. For instance, in a 
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randomised, double blind, placebo controlled study of 24 healthy subjects one week treatment 
with A4250 was found to be safe, well tolerated and produce significant decrease in plasma total 
BAs and FGF19 levels and increase plasma C4 (a marker of hepatic BA synthesis) and faecal 
BAs. The main adverse events were abdominal discomfort, nausea and mild diarrhoea which 
were dose-dependent[23]. GSK2330672 has been developed as specific, non-absorbable, highly 
potent human ASBTi [24] and has been investigated in double-blind, randomized trials of 
patients with type2 diabetes mellitus (T2DM) [25]. It was shown to reduce circulating BAs, 
fasting plasma glucose and cholesterol (LDL, non-HDL and total cholesterol) levels and increase 
C4. Diarrhoea was the most common adverse event associated with GSK2330672 which 
appeared to be dose-independent.  
Pruritus, a common and debilitating symptom associated with PBC and PSC is specifically being 
targeted with novel ASBTi. The rationale for this is cholestatic pruritus is linked to circulating 
BAs and reducing their levels may improve the symptom. The results of CLARITY study 
investigating use of oral Lopixibat chloride (LUM001) in PBC patients with pruritus was 
presented at the International Liver Congress (EASL 2016)[26]. In this double blind, randomised 
placebo controlled trial PBC patients on stable doses of UDCA (or intolerant to UDCA) with 
baseline pruritus score >4 for each of two consecutive weeks in the screening period were 
randomised to daily Lopixibat 10 mg, 20 mg or placebo. The 13-week treatment period 
comprised dose-escalation (3–4 weeks) and stable-dosing periods (9–10 weeks). The primary 
endpoint was change in adult ItchRO weekly sum score at week 13 or early termination. The 
results from 66 enrolled patients (61 completed the study) showed significant decrease in ItchRO 
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score from baseline in the within group comparison (26% Lopixibat, p<0.0001 and 23% placebo, 
p<0.0001) but no significant difference between group comparison (Lopixibat vs. placebo, 
p=0.47). The changes in serum ALP from baseline were not significant for either group but 
reduction in mean serum BA levels (-14.23 vs.10.05) and increase in C4 levels (13.49 vs. -2.21) 
were greater for Lopixibat group compared to placebo. GSK2330672 is also being investigated 
as a potential treatment for pruritus and a phase 2 randomised, double blind, placebo controlled 
cross-over trial in PBC patients with pruritus has recently been completed and the results are 
awaited[27].  
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Limitations 
There are few potential concerns with the use of ASBTi. Increased spill over of BAs in the colon 
is known to cause diarrhoea, which is an adverse event and may limit the regular use of the 
drugs. Long-term BA malabsorption resulting from ASBTi may produce fat soluble vitamin 
deficiencies, hyperoxaluria, urolithiasis and increased incidence of pigment and cholesterol 
gallstones[28]. More importantly, increased BAs in the colon may also have malignant potential 
for colorectal cancer (CRC) development and this risk needs careful evaluation. In a recent 
study, ASBT-deficient (Slc10a2−/−) mice showed a 54% increase in aberrant crypt foci (earliest 
histological marker of colon neoplasia) and 70% and 59% increase in colon tumour number and 
size, respectively[29]. Additionally, gut microbial dysbiosis has been linked to CRC [30,31] and 
ASBTi induced increased BA load in the colon may adversely affect the gut microbial diversity 
and increase the risk of CRC. However, there are no data to support or refute these hypothesis in 
the short-term human studies reported so far. Therefore, long-term clinical studies would be 
needed to fully understand the potential concerns of CRC with ASBTi.  
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Other therapies 
In addition to ASBTi, other attractive therapeutic agents for cholangiopathies include FXR 
agonists, FGF19 analogues, norUDCA, PPAR and TGR5 agonists[32]. The mechanism(s) of 
action of these drugs differs from that of ASBTi with primary effect on inhibiting hepatic BA 
synthesis and alter the load or composition of hepatic BA pool.  
As summarised in Table 3 the effects of these drugs on BA synthesis, serum BA and FGF19 
levels are contradictory and it is ironic that they are all being pursued with a common goal of 
improving cholestasis. For instance, ASBTi improve cholestasis (at least in animal models) but 
inhibit FGF19 production in contrast to FXR agonists which also improve cholestasis but 
stimulate the synthesis of FGF19. It is noteworthy that although FGF19 down-regulates BA 
synthesis it induces hepatocyte proliferation and prolonged exposure in animal studies has been 
shown to cause hepatocellular carcinoma [33]. This potential tumorigenic action of FGF19 is of 
a concern but circumvented by recent development of engineered FGF19 variants without 
mitogenic actions[34]. Pre-clinical studies suggest FGF19 analogues have potential in the 
treatment of PBC and PSC. It is equally intriguing that PBC patients treated with FXR agonist 
(obeticholic acid) that effectively inhibits BA synthesis developed pruritus as an adverse 
event[35] but ASBTi which cause rebound increase in BA synthesis are being developed to treat 
pruritus.  
In summary, the field of BA based therapeutics in cholestasis is evolving and drugs with 
paradoxical and diverse BA-mediated effects are being rapidly developed. In future, it is possible 
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that various combination therapies targeting BA homeostasis is the best way to effectively treat 
PBC and PSC[28].  
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Conclusion  
In the quest for novel therapies in PBC and PSC ASBT inhibitors are emerging as important 
therapeutic options. They block the uptake of BAs in the terminal ileum, increase their excretion 
in the faeces and decrease the amount of BAs returning to the liver via enterohepatic circulation. 
Experimental and early clinical studies confirm ASBT inhibitors are effective in reducing total 
BA levels with compensatory increase in hepatic BA synthesis. Reductions in total and LDL 
cholesterol are additional advantages which can help treat metabolic diseases. A variety of ASBT 
inhibitor compounds are emerging and their utility is now being explored across PBC and PSC 
as well as NASH, with a view to both reducing cholestatic and liver injury and also addressing 
pruritus management. BA induced diarrhoea is the main adverse event associated with ASBT 
inhibitors. Future long-term studies will need to explore the impact of these drugs on potential 
risk of colon cancer development. 
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Figure 1  
ASBT inhibitors selectively block the BA transporter ASBT located on the apical side of ileal 
enterocytes and inhibit BA re-uptake. As a result, BAs spill over into the colon and are lost via 
faeces. This reduces the amount of BAs returning to liver via portal circulation. 
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Table 1  
Different classes of ASBT inhibitors (ASBTi) 
Class Compound Comments Reference 
Dimeric bile acid 
analogues 
PB3, S0960,  [36-38] 
Benzothiazepine  
derivatives 
2164U90 
 
 
264W94 
competitive inhibitor 
of murine ASBT 
 
∼500-fold more 
potent inhibitor than 
2164U90 
 
[39,40] 
 
 
[41] 
Benzothiepine 
derivatives 
SC-435  potent and non-
absorbed 
 increases faecal 
BA excretion, 
decreases total and 
LDL-cholesterol 
plasma levels and 
enhances 
expression of the 
hepatic LDL 
receptor 
[19,20,42] 
Naphthol derivatives S8921 mixed competitive 
and non-competitive 
ASBT inhibitor 
[43,44] 
4-oxo-1-phenyl-1,4,-
dihydroquinoline 
derivatives 
/  [45] 
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Table 2  
ASBT inhibitors in clinical development  
Compound Sponsor Clinical trial 
number 
Phase Disease 
A4250 Albireo NCT02360852 2 Cholestatic pruritus 
  NCT02630875 2 Paediatric cholestasis 
GSK2330672 GlaxoSmithKline NCT01416324 1 Healthy subjects 
  NCT01929863 2 T2DM 
  NCT02202161 2 T2DM 
LUM001  
(SHP-625 or 
Lopixibat) 
Shire NCT01904058 2 PBC 
  NCT02061540 2 PSC 
  NCT01903460 
NCT02057692 
NCT02117713  
2 
 
Alagille Syndrome  
  
  NCT02057718 2  PFIC 
Volixibat  
(SHP-626)  
Shire NCT02787304 2 NASH 
 
Abbreviations: ASBT, apical sodium-dependent bile acid transporter; PBC, primary biliary cholangitis; 
PSC, primary sclerosing cholangitis; PFIC, progressive familial intrahepatic cholestasis ;T2DM, type 2 
diabetes mellitus 
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Table 3 
An overview of potential future therapies in cholestatic diseases 
 
 ASBT  
inhibitors 
FXR  
agonists 
FGF19  
analogues 
nor 
UDCA 
PPAR 
agonists 
TGR5  
agonists 
Examples Lopixibat chloride 
(LUM-001), 
GSK2330672 
INT-747 (Obeticholic 
acid, OCA), INT-767, 
GW4064, GSK2324, 
PX-102, MFA-1, 
Way362450, 
Fexaramine, LJN452, 
GS-9674 
NGM282,  
M70 
- Fenofibrate, 
bezafibrate, 
GFT505 
MBX-8025 
INT-777 
XL475 
Target 
disease(s) 
PBC, cholestatic 
pruritus 
PBC, PSC, NASH, PBC, PSC, NASH PSC, NASH PBC, PSC, 
NASH 
PSC, NASH 
Phase of 
development 
II III (OCA in PBC) II II II 
III (bezafibrate 
in PBC) 
Preclinical 
mechanism(s) 
of action 
↓ intestinal BA 
reabsorption 
↓ hepatic  
BA synthesis 
↓ hepatic  
BA synthesis 
‘cholehepatic 
shunting’, 
induces a 
bicarbonate- 
rich 
hypercholeresis 
↓ hepatic  
BA synthesis,  
anti-
inflammatory 
↑bile flow, 
anti-
inflammatory, 
↑energy 
expenditure, 
↑ GLP-1, 
↑ insulin 
sensitivity 
C4 levels¶ ↑ ↓ ↓ NA¥ NA NA 
Serum BA 
levels 
↓ ↓ ↓ NA ↓ NA 
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Serum FGF19 
levels 
↓ ↑ ↑ NA NA NA 
Adverse events 
(AEs) 
diarrhoea,  
abdominal pain 
pruritus  
(obeticholic acid) 
lower GI symptoms, 
diarrhoea 
No serious AEs Hepatotoxicity 
(fibrates) 
NA 
References [26] [35] [46] [47] [48,49] [49] 
 
Abbreviations: ASBT, apical sodium dependent BA transporter; BA, bile acid; GLP-1, glucagon-like-peptide-1; FGF, fibroblast growth factor; 
FXR, farnesoid X receptor; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PPAR, peroxisome proliferator-activated 
receptor; PSC, primary sclerosing cholangitis; TGR, transmembrane G protein-coupled receptor. 
 
NA, no available data  
 
¶ C4(7a-hydroxy-4-cholesten-3-one) is an intermediate in the hepatic BA synthesis pathway. Serum C4 levels act as surrogate marker for CYP7A1 
enzyme activity. 
 
¥ norUDCA has no relevant affinity to FXR, therefore unlikely to change hepatic BA synthesis. 
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